Sanofi CEO talks about the impact of AI and lung disease drug approval

Paul Hudson, CEO of Sanofi, talked with Caroline Hyde about the integration of AI tools into the company's daily operations, the impact of AI in the biopharmaceutical sector, and the fact that Dupixent, the company's blockbuster drug, was approved as a treatment for chronic lung disease in the European Union, opening a new path for the growth of this drug.